HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Circulating PGLYRP1 Levels as a Potential Biomarker for Coronary Artery Disease and Heart Failure.

AbstractABSTRACT:
Coronary artery disease (CAD) and associated comorbidities such as heart failure (HF) remain the leading cause of morbidity and mortality worldwide attributed to, at least partially, the lack of biomarkers for efficient disease diagnosis. Here, we evaluated the diagnostic potential of serum peptidoglycan recognition protein 1 (PGLYRP1), an important component of the innate immunity and inflammation system, for both CAD and HF. A machine-learning method (random forest) was used to evaluate the clinical utility of circulating PGLYRP1 for diagnosis of CAD and HF in a total of 370 individuals. Causal links of chronic serum PGLYRP1 elevation to both diseases were further explored in ApoE-/- mice. The serum levels of PGLYRP1 were significantly higher in individuals with either chronic CAD or acute coronary syndrome than those in those without coronary artery stenosis (the control group) and even more pronounced in CAD individuals with concomitant HF. Our random forest classifier revealed that this protein performed better than other recommended clinical indicators in distinguishing the CAD from the control individuals. In addition, this protein associates more with the biomarkers of HF including left ventricular ejection fraction than inflammation. Notably, our mice experiment indicated that long-term treatment with recombinant PGLYRP1 could significantly impair the cardiovascular system as reflected from both increased atherogenic lesions and reduced fractional shortening of the left ventricle. Our findings, therefore, supported the circulating levels of PGLYRP1 as a valuable biomarker for both CAD and HF.
AuthorsYanxin Han, Sha Hua, Yanjia Chen, Wenbo Yang, Weilin Zhao, Fanyi Huang, Zeping Qiu, Chendie Yang, Jie Jiang, Xiuxiu Su, Ke Yang, Wei Jin
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 77 Issue 5 Pg. 578-585 (05 01 2021) ISSN: 1533-4023 [Electronic] United States
PMID33760799 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Chemical References
  • Biomarkers
  • Cytokines
  • PGLYRP1 protein, human
Topics
  • Acute Coronary Syndrome (blood, diagnostic imaging)
  • Animals
  • Aorta (drug effects, metabolism, pathology)
  • Aortic Diseases (metabolism, pathology, prevention & control)
  • Atherosclerosis (metabolism, pathology, prevention & control)
  • Biomarkers (blood)
  • Case-Control Studies
  • Coronary Artery Disease (blood, diagnostic imaging)
  • Coronary Stenosis (blood, diagnostic imaging)
  • Cross-Sectional Studies
  • Cytokines (blood, pharmacology)
  • Disease Models, Animal
  • Heart Failure (blood, diagnosis)
  • Humans
  • Machine Learning
  • Male
  • Mice, Knockout, ApoE
  • Plaque, Atherosclerotic
  • Predictive Value of Tests
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: